

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/08178 A1

- (51) International Patent Classification⁷: **C07C 311/51**, A61K 31/18 // A61P 3/00 (74) Agent: **HÖGLUND, Lars**. Biovitrum AB, S-112 76 Stockholm (SE).
- (21) International Application Number: PCT/SE01/01651 (81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 19 July 2001 (19.07.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 0002754-0 21 July 2000 (21.07.2000) SE (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- (71) Applicant (*for all designated States except US*): **BIOVITRUM AB** [SE/SE], S-112 76 Stockholm (SE).
- (72) Inventors; and (75) Inventors/Applicants (*for US only*): **JOSSAN, Sukhwinder** [IN/SE], Skrinnavagen 8, S-756 47 Uppsala (SE) **NILSSON, Björn, M.** [SE/SE], Djaknegatan 15 650, S-754 23 Uppsala (SE) **SAKARIASSEN, Kjell, S.** [NO/SE], Hasselby Strandväg 74, S-165 65 Hasselby (SE). **SVARTENGREN, Jan** [SE/SE], Vaderkvarns-gatan48 A, S-753 26 Uppsala (SE)

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette

(54) Title: NEW COMBINATION OF SEROTONIN AGONIST (5HT₂) AND ANTAGONIST (5HT₆) AS PHARMACEUTICAL FORMULATION

(57) Abstract: The invention relates to a method of preventing or treating a disease related to the 5-HT_{2C} receptor and the 5-HT₆ receptor, comprising administering to a human or animal subject in need thereof a 5-HT_{2C} receptor agonist and a 5-HT₆ receptor antagonist in sufficient amounts to provide a therapeutic affect. The invention also relates to a pharmaceutical composition comprising an effective amount of a combination of a 5-HT_{2C} receptor agonist and a 5-HT₆ receptor antagonist, and optionally a pharmaceutically acceptable carrier.

WO 02/08178 A1